MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Olanzapine (Zyprexa®)

Selected References:

  • Ambresin G, et al. 2004. Olanzapine excretion into breast milk: a case report. J Clin Psychopharmacol; 24(1):93-5.
  • Aydin B, et al. 2015. Olanzapine and quetiapine use during breastfeeding: Excretion into breast milk and safe breastfeeding strategy. J Clin Psychopharmacol; 35:206-8.
  • Betcher HK, et. al 2020. Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. J Womens Health 29(3):310-318.
  • Brunner E, et al. 2013. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacology & Toxicology, 14, 1-8.
  • Croke S, et al. 2003. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol; 5:243-7.
  • Damkier P, et al. 2018. The safety of second-generation antipsychotics during pregnancy: a clinically-focused review. CNS Drugs 32:351-366.
  • Einarson A & Boskovic R. 2009. Use and safety of antipsychotics during pregnancy. Journal of Psychiatric Practice, 15, 183-192.
  • Ennis ZN, et al. 2014. Pregnancy exposure to Olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: A systemic review. Basic & Clinical Pharmacology & Toxicology. 116(4), 315-20.
  • Friedman SH, et al. 2017. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int J Psychiatry Med 51(6): 521-533.
  • Gilad O, et al. 2011. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeeding Medicine, 6, 55-58. doi: 10.1089/bfm.2010.0027.
  • Habermann F, et al. 2013. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol.33(4):453-62.
  • Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatr; 73(9):938-946.
  • Johnson KC et al. 2012. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 69(8):787-94.
  • Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. 6(10): 1221-1286.
  • Manouilenko I, et al. 2018. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. Arch Womens Ment Health; 21(5):587-589
  • McKenna K, et al. 2005. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. Journal of Clinical Psychiatry, 4, 444-449.
  • Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. J Clin Psychiat; 66:269-270.
  • Newport DJ, et al 2007. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes
  • Park Y, et al. 2018. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Psychiatry 175(6):564-574.
  • Reutfors J, et al. 2020 Antipsychotic drug use in pregnancy: A multinational study from 10 countries. Schizophr Res 220:106-115
  • Rubakowski J, et al. 2019. Recommendations of the Poliksh Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. Psychiatr Pol 53(2):263-276
  • Shao P, et al. 2015. Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis. PLoS One; 10(4).
  • Teodorescu A, et al. 2017. Dilemma of treating schizophrenia during pregnancy: a case series and a review of literature. BMC Psychiatry 17(1):311.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.